Mobilized peripheral blood progenitor cells (PBPC) from 30 patients with advanced breast cancer were studied for the presence of tumor cell contamination using a highly sensitive immunohistochemical technique with the capacity to detect one tumor cell in one million mononuclear cells. Aliquots of PBPC were obtained after 4 days of G-CSF and/or GM-CSF and again during G-CSF-stimulated recovery from myelosuppressive doses of cyclophosphamide. The overall incidence of tumor cell contamination was 23%, occurring in PBPC specimens from seven of 30 patients. All four cases in which tumor cells were detected after mobilization with cytokine alone also had tumor cells detected in PBPCs collected following chemotherapy and G-CSF. There were three cases in which malignant contamination was detected only in the specimens collected after cyclophosphamide. There was a greater frequency of tumor cell contamination in aphereses performed during G-CSFstimulated recovery from cyclophosphamide than in collections primed by cytokine alone (13% vs 23%; P = 0.08), although this did not reach statistical significance. This trend suggests that collection of PBPC during cytokine-stimulated recovery from myelosuppressive chemotherapy may be associated with a greater risk of contamination with malignant cells than apheresis during mobilization with cytokines in the steady state.
Malignant cells have been detected in the peripheral blood of patients with solid tumors such as breast and lung cancer and may contaminate peripheral blood progenitor cell (PBPC) collections in individuals undergoing high-dose chemotherapy with autologous stem cell reinfusion. 1, 2 The likelihood of tumor cell contamination of the apheresis product may be related to the particular mobilization protocol.
Brugger and colleagues 1 3 found immunohistochemical evidence of breast cancer in some patients undergoing apheresis during granulocyte-macrophage colony-stimulating factor (GM-CSF)-stimulated recovery from myelosuppressive doses of cyclophosphamide. Using historical controls, they compared the frequency with which tumor cells contaminated PBPC mobilized with cytokine alone in the steady state to that of PBPC mobilized with chemotherapy and growth factor and found no difference. 4 In contrast, mobilization with cytokine alone resulted in a higher rate of tumor cell contamination of PBPC collections than mobilization with chemotherapy-based regimens in a large multi-institutional series of women with stage IV disease. 5 Using a highly sensitive immunocytochemical technique, we evaluated the incidence of tumor cell contamination of PBPC specimens from patients with advanced breast cancer and investigated its relationship to the mobilization method. In the past, patients at our institution have been enrolled on protocols which specified PBPC mobilization with Gand/or GM-CSF. 6 Patients with advanced breast cancer then proceeded to 'chemomobilization' with cyclophosphamide (CY) and G-CSF. Consequently, we have had the unique opportunity to compare the incidence of tumor cell contamination of PBPC mobilized by cytokine alone in the steady state with that of PBPC mobilized by chemotherapy plus cytokine in the same individuals.
Materials and methods

Patient population
The subjects of this investigation were participants in a phase I/II study of high-dose chemotherapy and PBPC rescue for the treatment of advanced breast cancer. Eligibility criteria included age less than 60 years, histologically proven stage IIIB or IV breast cancer, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Optimal cardiac (normal left ventricular ejection fraction by nuclear scan), pulmonary (corrected diffusion capacity у50%), hepatic, and renal (serum creatinine Ͻ1.5 mg/dl) function was required. Written informed consent was obtained according to the requirements of the Northwestern University Institutional Review Board in all cases.
All patients underwent PBPC mobilization first with cytokines alone (G-CSF, and/or GM-CSF; Amgen, Thousand Oaks, CA, USA and Sandoz Pharmaceutical, East Hanover, NJ, USA; see Figure 1 ). These patients were enrolled on previous mobilization trials conducted at our institution and qualified for inclusion in this series if frozen ampules containing samples of the first apheresis (day 5) were available for study. 6 The mobilization regimen consisted of either G-or GM-CSF at either 5 or 10 g/kg or a combination of G-and GM-CSF, each at 5 g/kg. Given the laborious nature of the immunohistochemical assay, only the first apheresis (day 5 of cytokine administration) served as a representative source of PBPC for this investigation. After a 'wash-out' period of approximately 1 week, PBPC were mobilized by myelosuppressive doses of CY (4 g/m 2 ) followed by G-CSF 5 g/kg. Day 15 was prescribed as the required interval to apheresis to permit advanced scheduling of the procedures on weekdays, and was a sufficient interval from chemotherapy administration to allow for recovery of the white blood cell count in all cases. Patients subsequently received high-dose chemotherapy consisting of ifosfamide, carboplatin, and thiotepa followed by autologous PBPC reinfusion. Finally, previous sites of bulk disease (Ͼ3 cm) were irradiated.
Peripheral blood progenitor (PBPC) harvesting and storage
PBPC were harvested by 10 liter continuous flow leukapheresis using either the COBE Spectra (COBE, Lakewood, CO, USA) or the Fenwal CS 30000 (Fenwal Division, Baxter Healthcare Corp, Deerfield, IL, USA) and cryopreserved as previously described. 6 Two milliliter ampules of each PBPC collection were stored separately in the vapor phase of liquid nitrogen.
Immunocytochemical assay
A monoclonal antibody cocktail targeting heavy and light weight cytokeratin (anti-AE-1/AE-3; Biogenics, Cambridge, MA, USA) was applied to aliquots of PBPC obtained from patients on day 5 of cytokine mobilization and again during the G-CSF-stimulated recovery from myelosuppressive doses of CY (4 g/m 2 ; day 15). Two milliliter aliquots of cryopreserved PBPC were thawed in a 37°C water bath, washed twice in Iscove's solution, and then fixed in formalin. Each sample was pelleted by centrifugation at 4087 g for 10 min after the addition of formalin. The cell buttons were chemically dehydrated and infused with paraffin using a Leica tissue processor and embedded in paraffin. Each button was serially sectioned with approximately eight to 10 cross-sections mounted on each positively charged slide. The sections were stained for cytokeratin using a Ventanna automated immunostainer. Briefly, the slides were deparaffinized and hydrated using graded xylene and alcohol solutions. The slides were then placed on the immunostainer where the sections were stained by incubation with the monoclonal antibody cocktail AE1/AE3 at 37°C. The stain was developed using an avidin-biotin system and diaminobenzidine as the coloring agent, and the sections were counterstained with hematoxylin. The stained sections were reviewed by two investigators individually, one of whom was the reference pathologist (EW). Discrepancies were resolved by consensus review.
This immunocytochemical (ICC) assay was developed and validated with experiments in which PBPC specimens from Hodgkin's disease and non-Hodgkin's lymphoma patients were spiked with the MCF-7 breast cancer cell line over a wide range of dilutions and then stained with the monoclonal antibody cocktail as described above. Some of these spiked specimens underwent controlled rate freezing to confirm that the assay would detect breast cancer cells that were cryopreserved and then thawed. In addition, myeloma, leukemia and lymphoma cell lines (MM1.S, U266, and SU-DHL-4) each studied in triplicate served as negative controls.
Statistical analysis
The Pearson correlation coefficient and accompanying t-test for zero correlation was used to relate the expected number of MCF-7 cells per PBPC to the observed number of stained cells per section. 7 Differences in the incidence of tumor cell contamination between the two mobilization methods were tested using McNemar's test of concordance. 
Results
Immunocytochemical assay
The sensitivity of the assay was established by measuring the cell density and cross-sectional radius on 41 cross-sections of cell buttons produced from 2 ml PBPC specimens each containing 4 ϫ 10 7 cells/ml (data not shown). This volume yielded a cell button with a 2-3 mm radius consisting of 40-80 cells/mm. It was then estimated that each cross-section contained 60 000 to 180 000 cells depending on the cell density. Detection of one malignant cell per million PBPC would, therefore, be expected to occur once every five to 20 sections. To ensure detection of one malignant cell in one million PBPC, we therefore examined a minimum of 40 sections per case. The assay was then validated by examining multiple PBPC specimens from leukemia or lymphoma patients spiked with MCF-7 breast cancer cells at varying dilutions. The excellent correlation between the expected number of MCF-7 cells detected in control PBPC specimens spiked at known ratios and the number of stained tumor cells per section observed is shown in Figure 2 (r = Ϫ0.984; P Ͻ 0.0001). The specificity of the assay was confirmed by the absence of staining of unmanipulated PBPC specimens from patients with Hodgkin's disease and non-Hodgkin's lymphoma (n = 3), and of negative control PBPC specimens spiked with myeloma, lymphoma and leukemia cell lines (n = 3). Examples of negative and positive controls and a positive case are displayed in Figure 3 .
Immunodetection of breast carcinoma
Sixty paired specimens from 30 women with advanced breast cancer were examined. Patient characteristics are summarized in Table 1 . The majority of patients had stage IV disease (70%), although 37% of these patients had no evidence of disease at the time of transplant either because the single site of disease had been resected or a complete response had been obtained by conventional dose chemotherapy. Nearly all patients were previously treated for metastatic disease. Bone marrow involvement was detected on routine histology in only one case.
The overall incidence of tumor cell contamination in the 60 paired specimens detected by immunohistochemistry was 18%, occurring in PBPC from 11 of 60 specimens. There was a greater frequency of tumor cell contamination in aphereses performed during G-CSF-stimulated recovery from CY than in collections primed by cytokine alone (13% vs 23%; P = 0.08), although this did not reach statistical significance. This study consisting of 30 pairs has 80% power to detect a 13% difference in incidence in tumor cell contamination between the two mobilization methods (eg between 13% and 26%). In fact, the observed difference was slightly less than this (13% vs 23%) and therefore, did not reach statistical significance (P = 0.08). As shown in Table 2 , all four patients who had tumor cells detected in PBPC mobilized by cytokine alone also had tumor cells 
Clinical outcome
The median follow-up for all patients was 581 days, and the median time to relapse was 276 days. Two patients experienced early deaths from regimen-related toxicities. One heavily pretreated patient expired on day ϩ5 from cardiac failure and a second patient expired on day ϩ11, from sepsis, which rapidly progressed to multi-organ failure.
Although there was no difference in relapse rates or survival between the immunopositive and immunonegative groups, the number of patients was too small to make the comparison meaningful. 
Discussion
Treatment with myeloid colony-stimulating factors mobilizes small numbers of neoplastic cells into the peripheral blood along with hematopoietic progenitors resulting in malignant contamination of PBPC autografts. 1,2 Whether or not there is a relationship between the method of mobilization and the likelihood of tumor cell contamination is currently under investigation. Given the unique design of our mobilization trials, we have had the opportunity to compare tumor cell contamination associated with mobilization by myeloid colony-stimulating factors (G-and/or GM-CSF) in the steady state and that associated with subsequent chemomobilization by myelosuppressive chemotherapy followed by G-CSF in the same individuals. Whereas the mobilization of tumor cells is likely to be related to clinical variables such as stage, sites of disease and prior treatment, we minimized the effect of confounding variables associated with a comparison of two groups of individuals by having each patient serve as her own control. Our study showed a greater frequency of tumor cell contamination in aphereses performed during G-CSF-stimulated recovery from CYinduced myelosuppression (P = 0.08), than in collections primed by cytokine alone, although this did not reach statistical significance. The mechanism for tumor cell mobilization into the peripheral blood is unknown, but may be a function of cytokine-mediated alterations in adhesion molecules or homing receptors that are characteristic of both tumor and hematopoietic cells. 8 Our study design was unique in that patients underwent two separate mobilizations, and thus served as their own controls. The clinical trial was designed, however, to address issues related to PBPC mobilization and not tumor cell contamination. The immunohistochemical assay is labor intensive leading us to limit our examination for neoplastic contamination to only the first apheresis obtained during mobilization with cytokine alone. If mobilization of malignant cells occurred with a longer period of CSF administration, we may have missed it by not examining the later PBPC collections. The possibility of synergy between the two mobilization methods must also be considered. The effects of the initial cytokine-only mobilization may not have dissipated completely during the 1 week wash-out period. Alternatively, the malignant cells found in PBPC mobilized by chemotherapy plus G-CSF may rep-resent a late 'wave' of tumor cell contamination of the peripheral blood related to the prior treatment with myeloid CSFs. Whereas this study was performed retrospectively on stored specimens, it was not possible to reverse the order of the two mobilization methods to control for these effects. Apheresis was prescheduled on day 15 following CY to ensure weekday collections. Although this was a sufficient interval from chemotherapy administration to allow for recovery of the white blood cell count in all cases, it may not have been the optimal day for collection of PBPC in all cases. Lastly, G-and GM-CSF may have different effects on the mobilization of breast cancer cells that cannot be ascertained in this study because of the small sample size.
Malignant cells were detected immunohistochemically in one-third of the cases from women with stage IV disease (seven of 21), despite the absence of bone marrow involvement by routine histopathology. This is a higher rate of involvement than that reported by Ross et al 2 (22%), Passos-Coelho et al 4 (8%) and by Pecora and colleagues 5 (23%), and may reflect differences in the patient population especially the bulk of residual disease. The majority of our patients had been previously treated for metastatic disease and visceral metastases were common. Our finding that all patients with locally advanced disease had negative assays supports the relationship between tumor bulk and a positive immunohistochemical assay. The extent to which small numbers of tumor cells in the autograft alter clinical outcome for patients undergoing high-dose chemotherapy with stem cell rescue for advanced stage breast cancer is as yet undetermined. The total number of patients studied in this series was insufficient to make meaningful comparisons regarding relapse rates, time to relapse, or survival between the immunopositive and immunonegative groups. Immunohistochemical or molecular detection of subclinical breast cancer in bone marrow autografts has been associated with a shortened survival in some series. [9] [10] [11] Data regarding the prognostic significance of subclinical neoplastic involvement of PBPC autografts are limited, but in at least one reported study of patients with breast cancer undergoing chemomobilization, contamination of the apheresis was associated with early relapse. 12 In contrast, neoplastic contamination of the reinfused stem cell product did not adversely affect clinical outcome for 57 patients with chemosensitive metastatic breast cancer receiving either bone marrow and/or PBPC autograft. 13 In this study, PBPC contamination with neoplastic cells occurred more commonly after myelosuppressive chemotherapy and G-CSF than with cytokine alone, although this difference did not reach statistical significance. Larger studies in which the mobilization methods are alternately reversed will be required to determine if, in fact, chemomobilization more effectively mobilizes tumor cells than cytokine alone.
